Cytoclonal Pharmaceutics Appoints Robert J. Rousseau, Ph.D. Vice President of Business Development and Licensing.
DALLAS--(BUSINESS WIRE)--March 6, 2001
Cytoclonal Pharmaceutics Inc. (Nasdaq:CYPH) announced today the appointment of Robert J. Rousseau, Ph.D. as Vice President of Business Development and Licensing. In this capacity Dr. Rousseau will be actively involved in business development and licensing opportunities with universities and biotechnology and pharmaceutical companies. Dr. Rousseau served as Director of New Technologies Licensing at Hoechst Marion Roussel, Inc. and has an MBA from Rockhurst University and a Ph.D. in Chemistry from the University of Utah.
"The combination of Dr. Rousseau's experience in licensing at the pharmaceutical company Hoechst Marion Roussel, coupled with his Ph.D. in organic chemistry, is a major asset for Cytoclonal," said Arthur P. Bollon, Ph.D., President, Chief Executive Officer, and Vice Chairman of Cytoclonal. "This is especially true for pursuing business opportunities for our various programs such as our proprietary drug design technology, Quantum Core Technology(TM)."
Dr. Rousseau commented, "Cytoclonal Pharmaceutics represents a unique opportunity to be part of a young, dynamic company with `exciting technology,' a bright and motivated diverse group of scientists and a clear focus toward future new pharmaceutical products."
Dr. Rousseau founded Rondeau Medical Associates Inc., a consulting company involved in new technology identification, development of an extensive contact network and establishment of licensing agreements for numerous biotechnology and pharmaceutical companies. Prior to Rondeau, he managed the gene transcription modulator-outlicensing program for OSI Pharmaceuticals, Inc., resulting in licensing agreements with Merck Sharp & Dohme, Pharmacia and Upjohn, Johnson & Johnson, American Home Products and Aurora Biosciences. Prior to OSI, he spent 12 years as Director of New Technologies Licensing at Hoechst Marion Roussel, Inc. where he was responsible for closing agreements with Immulogic, TransKaryotic Technologies (TKT), Albany Molecular Research and Development, Scios Nova, Gensia, Affymax, Oncogene Sciences (OSI) and Alliance Pharmaceuticals. Dr. Rousseau's previous positions included both Director of Operations and Director of Marketing at Analytical Systems, Division of Marion Laboratories; Director of Clinical Chemistry Research/Director of West Coast Operations, Hyland Division of Baxter Travenol; Technical Liaison Officer, Curtis Nuclear Corporation; and Head of BioOrganic Chemistry, ICN Nucleic Acid Research Institute.
Dr. Rousseau is the holder of seven patents, the author of more than 33 scientific publications and the recipient of two Presidential Awards and three Special Achievements Awards from Marion Laboratories.
Cytoclonal Pharmaceutics is a biopharmaceutical company specializing in the development of therapeutic products for the treatment and prevention of cancer, infectious and genetic diseases. www.cytoclonal.com.
Except for historical information, the matters discussed in this news release may be considered "forward looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results.